Skip to main content

Lupus clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for
  • Omega-3 Replacement With Krill Oil in Disease Management of SLE

    open to eligible people ages 18 years and up

    A randomized, double-blind controlled, multicenter study in SLE patients given AKBM-3031or placebo for 24 weeks (randomized period) and followed by an open label extension (OLE) treatment with AKBM-3031 for the next 24 weeks. Patients will be maintained on stable doses of background medications, except for glucocorticoids. Decreases in doses of glucocorticoids will be encouraged during the first 20 weeks of both the randomized and open label extension portions of the trial. Stable doses of glucocorticoids and other background medications are required during weeks 20-22 and 44-48.If indicated by the PI, brief increases in corticosteroids are permitted during the first 20 weeks of both the blinded and open label extension portion of the trial. The increase in prednisone (or equivalent) dose is limited to 2X the back-ground level to a maximum of20 mg/day for a maximum of 1 week (7 days) or to a single administration of intravenous methylprednisolone or equivalent at a maximum dose of 500mg. Stable doses of glucocorticoids and other background medications are required during weeks 20-22 and 44-48

    Orange, California and other locations

  • An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus

    Sorry, in progress, not accepting new patients

    This study will investigate BMS-986165 to assess its effects in patients with systemic lupus erythematosus (SLE).

    Orange, California and other locations

Last updated: